The ISR Immunolide Platform Expanded into Hepatitis B
Screenings of the substances from ISR’s Immunolide platform have identified a new pharmaceutical lead candidate, ISR051, which has immune stimulating effects, apparently advantageous in the treatment of hepatitis B. ISR now plans to expand its research and development portfolio to encompass, apart from HIV, tuberculosis and cancer, also hepatitis B.
The hepatitis B virus (HBV) is one of the world’s most ubiquitous diseases, where WHO estimates over two billion people have or have had the disease and 240 million are chronic bearers. Nearly 700,000 people die in this disease every year, and 25% of the chronically infected develop liver cirrhosis or hepatic cancer. Vaccinations against hepatitis B are successful, but there’s no curative treatment.
”ISR’s pediment is the comprehension of the activation and regulation of the immune system, where the company’s investments to develop its own pharmaceutical platforms have come into fruition. The lead compound ISR051 will now be developed and brought forward to clinical drug trial for the indication hepatitis B. We’re aware of the immense interest for this indication in Asia”, comments Ola Winqvist, CEO ISR.
This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU’s Market Abuse Regulation (MAR), and the Market Abuse Act. The information was sent in for publication through the above contact person on 4th October 2018; 08.48 AM.
För ytterligare information, vänligen kontakta:
Ola Winqvist, VD
ISR Immune System Regulation Holding AB (publ)
Email: info@israb.se
Phone: +46 (0) 70 54 27 939
Address:
Rörstrandsgatan 58
113 40 Stockholm, Sweden
About ISR Immune System Regulation Holding AB (publ)
ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceutics. Erik Penser Bank is the company’s Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.
Tags: